Risk of colorectal cancer in patients with hematologic disease

Kishida, Teruyuki; Yonezawa, Masaoki; Shibata, Yoshiaki; Tanaka, Shu; Shinozawa, Isao; Hoshino, T.; Tatsuguchi, Atsushi; Liu, Feng; Sato, Jun; Fujimori, Shunji; Yoshida, Yutaka; Sakamoto, Choitsu; Kobayashi, Masafumi

doi:10.1046/j.1440-1746.2000.2348.x

Cited by 5 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal cancer risk was increased by 50% five years after MM diagnosis. Similarly, a retrospective Japanese study also demonstrated a significantly increased risk of colorectal cancer following MM diagnosis between 1984 and 1994, which may be due to associated immunologic abnormalities between both diseases [11]. However, in a similar epidemiological study of German and Swedish MM patients, the SIR was increased for kidney and nervous system cancers with decreased SIR for colorectal cancers [9].…”

Section: Discussionmentioning

confidence: 88%

Colorectal Cancer in a Patient With Multiple Myeloma: A Treatment Dilemma

Kou¹,

Romain²,

Broadwater³

et al. 2020

Cureus

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 88%

Colorectal Cancer in a Patient With Multiple Myeloma: A Treatment Dilemma

Kou¹,

Romain²,

Broadwater³

et al. 2020

Cureus

View full text Add to dashboard Cite

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics

Razavi

Rand

Cozen

et al. 2013

Blood Cancer Journal

View full text Add to dashboard Cite

Recent studies have reported an increased risk of second primary malignancies (SPM) following multiple myeloma (MM) diagnosis associated with novel anti-myeloma treatments. We evaluated the risk of SPM among 36 491 MM cases reported to the Surveillance, Epidemiology, and End Results program (SEER) between 1973 and 2008. We calculated overall and site-specific standardized incidence ratio (SIR) and 95% confidence intervals (CI) for 2012 SPM cases diagnosed within the 35-year follow-up. There was no significant overall risk of SPM (SIR=0.98; 95% CI=0.94–1.02); however, there were multiple site-specific risk patterns. The risk of breast and prostate cancer was significantly decreased overall and across age, latency and the year of diagnosis strata. There was an ∼50% increased risk of colorectal cancer 5 years after MM diagnosis (Ptrend<0.001). The risk of hematological malignancies was significantly increased, notably for acute myeloid leukemia (AML; SIR=6.51; 95% CI=5.42–7.83). There was a significant decreasing trend for AML over time, particularly for patients ⩾65. However, no significant change in risk was noted after the introduction of autologous stem cell transplant among younger patients (<65 years). On the basis of observed trends for overall SPM as well as AML, no association between the introduction of novel therapies and SPM following MM has emerged in this large population-based study.

show abstract

Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma

Hasskarl

Ihorst

Pasquale

et al. 2010

Leukemia & Lymphoma

View full text Add to dashboard Cite

Multiple myeloma (MM) has been suggested to be associated with different neoplasms. Of 589 consecutive patients with MM, 59 (10%) had different neoplasms: solid tumors in 78% and hematological neoplasms in 22%. Different neoplasms were separated into those emerging prior or synchronously (p/s; n = 41) versus subsequently after the MM (n = 18). The rate of different neoplasms at the time of MM diagnosis was estimated as 6.6%, and estimated different neoplasm rates at 2, 5, and 10 years were 7.8%, 10.3%, and 11.6%, respectively. Patients with MM with p/s different neoplasms showed a hazard ratio (HR) for impaired overall survival of 1.2 (95% CI 0.8-2.0), whereas in those with subsequent neoplasms the HR was 2.5 (95% CI 1.4-4.4). This demonstrates that (1) p/s are more frequent compared with subsequent different neoplasms, and (2) the prognosis is more impaired with subsequent different neoplasms. Age ≥60 years was a confounding covariable with a HR of 2.021 (95% CI 1.6-2.6).

show abstract

Risk of colorectal cancer in patients with hematologic disease

Abstract: It is possible that a relatively large number of patients with pure red cell aplasia, multiple myeloma or aplastic anemia will develop a colorectal cancer.

Cited by 5 publications

References 32 publications

Colorectal Cancer in a Patient With Multiple Myeloma: A Treatment Dilemma

Colorectal Cancer in a Patient With Multiple Myeloma: A Treatment Dilemma

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics

Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma

Contact Info

Product

Resources

About